Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMMART-ACT: Personalized Cancer Treatment
NCT05238831Phase 1Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Irreversible Covalent Inhibitors, Antibody-Drug Conjugates (ADCs), Targeted Protein Degraders (TPDs)
01
Overview
Phase 1, open-label, single-arm trial of alectinib, alpelisib, anastrozole, atezolizumab, bevacizumab and 20 more in breast carcinoma, ovarian carcinoma, pancreatic carcinoma and 2 more, sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation at 2 years. Planned start Jan 2023; status: withdrawn.
02
Drugs
alectinibalpelisibanastrozoleatezolizumabbevacizumab
03
Conditions
breast carcinomaovarian carcinomapancreatic carcinomaprostate carcinomasarcoma
Beyond the preview
Go deeper on NCT05238831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238831.